LP220476-8
Cetuximab
Active
Description
Cetuximab is a monoclonal antibody used to treat advanced squamous cell carcinoma of the head and neck (SCCHN) and metastatic colorectal cancer (mCRC). Cetuximab competes to bind to the epidermal growth factor receptor (EGRF) and then subsequently inhibits tumor growth and metastasis. Cetuximab is used in conjunction with radiation in the treatment of SCCHN. It is also used as the sole therapy for SCCHN in instances of recurrent or metastatic disease where platinum-based therapy was not effective. In patients with mCRC cetuximab is used in combination with irinotecan or by itself in patients who are unable to tolerate irinotecan. PMID: 18034592 Some patients develop treatment-related hypersensitivity to
cetuximab and detection of anti-cetuximab IgE may help physicians identify patients at risk of a severe infusion reaction. PMID: 25471028
Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- Cetuximab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2016-07-12
- Construct for LOINC Short Name
- Cetuximab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP220476-8
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| zh-CN | Chinese (China) | 西妥昔单抗 Synonyms: 西妥昔单克隆抗体; |
| es-ES | Spanish (Spain) | Cetuximab |
| it-IT | Italian (Italy) | Cetuximab |
| nl-NL | Dutch (Netherlands) | cetuximab |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright